Medical treatment of uric acid kidney stones

Authors

  • Michel Normand Clinique Saint-Privat, 10 rue Margeride, 34760 Boujan sur Libron, France
  • Jean-Philippe Haymann Tenon Hospital, APHP, 4 rue de la Chine, 75020 Paris, France https://orcid.org/0000-0002-2756-2287
  • Michel Daudon Tenon Hospital

DOI:

https://doi.org/10.5489/cuaj.8774

Keywords:

Uric acid urolithiasis. acidic urinary pH. ammonia genesis. urine alkalization. potassium citrate

Abstract

INTRODUCTION: The prevalence of uric acid (UA) stones increases regularly due to its high correlation with obesity, hypertension, metabolic syndrome, type 2 diabetes, and aging. Uric acid stone formation is mainly due to an acidic urinary pH secondary to an impaired urinary ammonium availability responsible for UA rather than soluble urate excretion. Alkalization of urine is therefore advocated to prevent UA crystallization and considered effective therapy.

METHODS: We report a large series of 120 patients with UA lithiasis who were successfully treated with potassium (K)-citrate for stone dissolution (n=75) and/or stone recurrence prevention (n=45) without any urologic intervention, with a median 3.14 years followup. The K-citrate was diluted in 1.5 L of water, avoiding gastrointestinal disorders.

RESULTS: Among 75 patients having stones in their kidney at initiation of therapy, a complete chemolysis was obtained in 88% of cases. Stone risk factors decreased under treatment, mainly due to increased diuresis, urinary pH, and citrate excretion. Treatment was stopped in only 2% of patients due to side effects, with no hyperkalemia onset despite a median urinary potassium increase of 44 mmol/day.

CONCLUSIONS: Contrary to other reports, our data show that medical treatment of UA kidney stones is well-tolerated and efficient if regular monitoring of urinary pH is performed.

Downloads

Download data is not yet available.

Author Biographies

Michel Normand, Clinique Saint-Privat, 10 rue Margeride, 34760 Boujan sur Libron, France

Urology department

 

Jean-Philippe Haymann, Tenon Hospital, APHP, 4 rue de la Chine, 75020 Paris, France

Chief of the Physiology Department

Downloads

Published

2024-06-17

How to Cite

Normand, M., Haymann, J.-P., & Daudon, M. (2024). Medical treatment of uric acid kidney stones. Canadian Urological Association Journal, 18(11), E339–45. https://doi.org/10.5489/cuaj.8774

Issue

Vol. 18 No. 11 (2024): CUAJ November

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.